Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor
KIELPIN, Poland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116. CPL’116 was administered orally in single ascending doses in healthy …